13 December 2013Americas

Davis LLP bolsters life sciences team

Canadian law firm Davis LLP has strengthened its life sciences department with the addition of Sara Zborovski as partner.

Zborovski assists companies in navigating the regulatory landscape imposed by the Food and Drugs Act and advocates before all branches of Health Canada on behalf of the food and beverage, pharmaceutical, medical device and cosmetic industries.

Rob Seidel, QC, managing partner at Davis, said adding Zborovski to its team would “bring further depth and breadth” to the firm.

"Our clients will benefit from Sara's background and extensive experience acting on matters related to Health Canada issues, as well as her understanding of the regulatory and commercial environment in which they operate," Seidel said.

Davis recently made further additions to its IP and life sciences capabilities with the hiring of Andy Radhakant, Julian Worsley and Neil Fineberg as partners.

Davis LLP is a full-service national law firm with more than 250 lawyers across Canada and in Tokyo, Japan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 April 2026   The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.
Americas
29 April 2026   The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.
Americas
28 April 2026   Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug